Results 221 to 230 of about 246,925 (304)

A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome

open access: yesBritish Journal of Haematology, EarlyView.
Fostamatinib had 46% durable response, with 73% steroid reduction, in this multicentre retrospective study of refractory wAIHA/ES. Hypertension, gastrointestinal (GI) distress and neutropenia occurred in 23%. Only one patient required drug discontinuation and one patient dose reduction.
Jorge N. Ruiz Lopez   +16 more
wiley   +1 more source

A luminal non‐coding RNA‐based genomic classifier confirms favourable outcomes in patients with clinically organ‐confined bladder cancer treated with radical cystectomy

open access: yesBJU International, Volume 135, Issue 4, Page 648-656, April 2025.
Objective To further evaluate a genomic classifier (GC) in a cohort of patients undergoing radical cystectomy (RC), as long non‐coding RNA (lncRNA)‐based genomic profiling has suggested utility in identifying a distinct tumour subgroup corresponding to a favourable prognosis in patients with bladder cancer.
Joep J. de Jong   +14 more
wiley   +1 more source

Regulation of pexophagy by a novel TBK1-MARCHF7-PXMP4-NBR1 axis in PEX1-depleted HeLa cells. [PDF]

open access: yesAutophagy
Kim YH   +10 more
europepmc   +1 more source

Proteomic profile of CSF obtained at the time of diagnosis determines amyotrophic lateral sclerosis progression and survival: CXCL7 levels in disease prognosis and survival

open access: yesBrain Pathology, EarlyView.
Untargeted multiomic profiling of cerebrospinal fluid reveals that proteomic, but not lipidomic, signatures robustly distinguish ALS patients from controls and stratify individuals by survival, highlighting marked molecular differences between short survival and long survival disease.
Sergio Roca‐Pereira   +19 more
wiley   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

open access: yesBritish Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli   +7 more
wiley   +1 more source

Cannabidiol and cannabigerol ameliorate steatotic liver disease via phosphocreatine buffering and lysosomal restoration

open access: yesBritish Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) and cannabigerol (CBG) alleviate hepatic steatosis in obese mice by shifting energy buffering towards phosphocreatine and enhancing lysosomal lipid degradation and trafficking. These effects are associated with increased creatine kinase activity and lysobisphosphatidic acid (LBPA) levels, highlighting a previously unrecognised ...
Radka Kočvarová   +12 more
wiley   +1 more source

Schedule‐dependent neuroprotection by pioglitazone in a novel model of α‐synucleinopathy in rats: Integrated behavioural and histological outcomes

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose α‐Synucleinopathies are neurodegenerative disorders characterized by the aggregation and propagation of misfolded α‐synuclein. In Parkinson's disease (PD), the most common α‐synucleinopathy, the progression of motor and nonmotor deficits, and dopaminergic neuron loss, are closely linked to the spreading of misfolded α‐synuclein ...
Alberto Santiago‐Balmaseda   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy